VEVincent Ehreiser

Vincent Ehreiser

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Vincent Ehreiser has a total of 88 co-authors. Here are the top co-authors by number of shared publications:

  • Tobias Petzold

    Department of Cardiology, Angiology and Intensive Care Medicine - Deutsches Herzzentrum der Charité (DHZC), University Medical Center Berlin, Campus Benjamin Franklin, Berlin, Germany

    3 shared publications
  • Konstantin Stark

    Department of Cardiology, University Hospital, LMU Munich, 81377 Munich, Germany

    2 shared publications
  • Leo Nicolai

    Medizinische Klinik und Poliklinik I, University Hospital Ludwig Maximilian University, Munich, Germany

    2 shared publications
  • Steffen Massberg

    Department of Medicine I, LMU University Hospital, Ludwig Maximillian University of Munich, Munich, Germany

    2 shared publications
  • Zhe Zhang

    Medizinische Klinik und Poliklinik I, Klinikum der Universität München, Ludwig-Maximilians- University Munich, 81377 Munich, Germany; Institute of Surgical Research at the Walter-Brendel-Centre of Experimental Medicine, Klinikum der Universität München, Ludwig-Maximilians- University Munich, 81377 Munich, Germany

    2 shared publications
  • Afra Anjum

    Department of Medicine I, Ludwig Maximilian University Hospital, Ludwig Maximilian University Munich, Munich, Germany

    1 shared publication

Latest Publications

  • Top Cited Papers

    Immobility-associated thromboprotection is conserved across mammalian species from bear to human

    by Manuela Thienel, Johannes B. Müller-Reif, Zhe Zhang, Vincent Ehreiser, Judith Huth, Khrystyna Shchurovska, Badr Kilani, Lisa Schweizer, Philipp E. Geyer, Maximilian Zwiebel, et al.

    Venous thromboembolism (VTE) comprising deep venous thrombosis and pulmonary embolism is a major cause of morbidity and mortality. Short-term immobility-related conditions are a major risk factor for the development of VTE. Paradoxically, long-term immobilized free-ranging hibernating brown bears and paralyzed spinal cord injury (SCI) patients are protected from VTE. We aimed to identify mechanisms of immobility-associated VTE protection in a cross-species approach. Mass spectrometry–based proteomics revealed an antithrombotic signature in platelets of hibernating brown bears with heat shock protein 47 (HSP47) as the most substantially reduced protein. HSP47 down-regulation or ablation attenuated immune cell activation and neutrophil extracellular trap formation, contributing to thromboprotection in bears, SCI patients, and mice. This cross-species conserved platelet signature may give rise to antithrombotic therapeutics and prognostic markers beyond immobility-associated VTE.


  • Open Access

    Neutrophil “plucking” on megakaryocytes drives platelet production and boosts cardiovascular disease

    by Tobias Petzold, Zhe Zhang, Iván Ballesteros, Inas Saleh, Amin Polzin, Manuela Thienel, Lulu Liu, Qurrat Ul Ain, Vincent Ehreiser, Christian Weber, et al.


  • Open Access

    Thrombocytopenia and splenic platelet-directed immune responses after IV ChAdOx1 nCov-19 administration

    by Leo Nicolai, Alexander Leunig, Kami Pekayvaz, Max Esefeld, Afra Anjum, Justina Rath, Eva Riedlinger, Vincent Ehreiser, Magdalena Mader, Luke Eivers, et al.

    Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are based on a range of novel platforms, with adenovirus-based approaches (like ChAdOx1 nCov-19) being one of them. Recently, a novel complication of SARS-CoV-2–targeted adenovirus vaccines has emerged: immune thrombocytopenia, either isolated, or accompanied by thrombosis (then termed VITT). This complication is characterized by low platelet counts, and in the case of VITT, also by platelet-activating platelet factor 4 antibodies reminiscent of heparin-induced thrombocytopenia, leading to a prothrombotic state with clot formation at unusual anatomic sites. Here, we detected antiplatelet antibodies targeting platelet glycoprotein receptors in 30% of patients with proven VITT (n = 27) and 42% of patients with isolated thrombocytopenia after ChAdOx1 nCov-19 vaccination (n = 26), indicating broad antiplatelet autoimmunity in these clinical entities. We use in vitro and in vivo models to characterize possible mechanisms of these platelet-targeted autoimmune responses leading to thrombocytopenia. We show that IV but not intramuscular injection of ChAdOx1 nCov-19 triggers platelet-adenovirus aggregate formation and platelet activation in mice. After IV injection, these aggregates are phagocytosed by macrophages in the spleen, and platelet remnants are found in the marginal zone and follicles. This is followed by a pronounced B-cell response with the emergence of circulating antibodies binding to platelets. Our work contributes to the understanding of platelet-associated complications after ChAdOx1 nCov-19 administration and highlights accidental IV injection as a potential mechanism of platelet-targeted autoimmunity. Hence, preventing IV injection when administering adenovirus-based vaccines could be a potential measure against platelet-associated pathologies after vaccination.